ArticleMolecular therapy : the journal of the American Society of Gene Therapy2010
A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 72 citations in OpenAlex.
- Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.Human gene therapy · 2013Trial
- Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols.The veterinary quarterly · 2025Article
- Involvement of TGF-β, mTOR, and inflammatory mediators in aging alterations during myxomatous mitral valve disease in a canine model.GeroScience · 2025Review
- Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.Animals : an open access journal from MDPI · 2025Review
- Linear DNA amplicons as a novel cancer vaccine strategy.Journal of experimental & clinical cancer research : CR · 2022Article
- COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy.Pharmaceutics · 2021Review
- Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.Frontiers in veterinary science · 2021Review
- Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study.Journal of translational medicine · 2020Article
- Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2019Review
- Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers.Journal for immunotherapy of cancer · 2019Article
- Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth.Journal of experimental & clinical cancer research : CR · 2019Article
- A Role for Dogs in Advancing Cancer Immunotherapy Research.Frontiers in immunology · 2019Review
- Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma.Journal of translational medicine · 2018Article
- Molecular cloning of canine Wilms' tumor 1 for immunohistochemical analysis in canine tissues.The Journal of veterinary medical science · 2017Article
- Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.Veterinary sciences · 2015Article
- Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model.Cancer immunology, immunotherapy : CII · 2015Article
- The importance of comparative oncology in translational medicine.Cancer immunology, immunotherapy : CII · 2015Review
- On the potential of oncolytic virotherapy for the treatment of canine cancers.Oncolytic virotherapy · 2015Review
- Oncolytic virotherapy of canine and feline cancer.Viruses · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine cancers occur with an incidence similar to that of humans and share many features with human malignancies including histological appearance, tumor genetics, biological behavior, and response to conventional therapies. As observed in humans, the telomerase reverse transcriptase (TERT) activity is largely confined to tumor tissues and absent in the majority of normal dog tissues. Therefore, dog TERT (dTERT) can constitute a valid target for translational cancer immunotherapy. We have evaluated the ability of adenovirus serotype 6 (Ad6) and DNA electroporation (DNA-EP) to induce immune responses against dTERT in dogs affected by malignant lymphoma (ML). The vaccine was combined with standard chemotherapy regimen [cyclophosphamide, vincristine, prednisone (COP)]. dTERT-specific immune response was induced in 13 out of 14 treated animals (93%) and remained detectable and long-lasting with the absence of autoimmunity or other side effects. Most interestingly, the survival time of vaccine/Chemo-treated dogs was significantly increased over historic controls of Chemo-treated animals (>97.8 versus 37 weeks, respectively, P = 0.001). Our results show that Ad6/DNA-EP-based cancer vaccine against dTERT overcomes host immune tolerance, should be combined with chemotherapy, induces long-lasting immune responses, and significantly prolongs the survival of ML canine patients. These data support further evaluation of this approach in human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.